杨士伟,周玉杰

• 1:首都医科大学附属北京安贞医院心内科

摘要(Abstract)：

<正>1他汀——自然界送给人类的完美礼物1976年,日本三共制药公司的生物化学家Endo经过6000多次科学实验,在真菌(penicillium citrinum)培养液中偶然提取出了一种新的次生代谢产物——ML-236B,能够抑制胆固醇合成过程中的限速酶3-羟基3-甲基戊二酰辅酶A还原酶(HMG-CoA),从而使胆固醇的合成减少50%。ML-236B后来被命名为康帕丁(compactin)、美

关键词(KeyWords)：

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金(81100143);; 北京市教委重点项目(KZ201110025031);; 首都临床特色应用研究重点项目(Z0005190042811);; 北京市科技新星(Z121107002512053)

作者(Author): 杨士伟,周玉杰

参考文献(References)：

• [1]Kannel WB,Dawber TR,Friedman GD,et al.Risk factors in coronary heart disease.An evaluation of several serum lipids as predictors of coronary heart disease;the framingham study[J].Ann Intern Med,1964,61:888-899.
• [2]McKenneyJM.Newguidelinesformanaginghypercholesterolemia[J].J Am Pharm Assoc(Wash),2001,41(4):596-607.
• [3]Grundy SM,Cleeman JI,Merz CN,et al.Implications of recent clinical trials for the national cholesterol education program adult treatment panelⅢguidelines[J].Circulation,2004,110:227-239.
• [4]Reiner Z,Catapano AL,De Backer G,,et al.Esc/eas guidelines for the management of dyslipidaemias:The task force for the management of dyslipidaemias of the european society of cardiology(esc)and the european atherosclerosis society(eas)[J].Eur Heart J,2011,32(14):1769-1818.
• [5]Violi F,Micheletta F,Iuliano L.Mrc/bhf heart protection study[J].Lancet,2002,360(9347):1782-1783;author reply 1783-1784.
• [6]Brown MJ.Mrc/bhf heart protection study[J].Lancet,2002,360(9347):1782,author reply1783-1784.
• [7]Bates CJ.Mrc/bhf heart protection study[J].Lancet,2002,360(9347):1781-1782,author reply1783-1784.
• [8]Durrington PN.Mrc/bhf heart protection study[J].Lancet,2002,360(9347):1781,author reply1783-1784.
• [9]Wald N,Law M.Mrc/bhf heart protection study[J].Lancet,2002,360(9347):1781,author reply1783-1784.
• [10]Robins SJ,Despres JP.Mrc/bhf heart protection studyv[J].Lancet,2002,360(9347):1780,author reply1783-1784.
• [11]Vaughan CJ,Buckley BM.Mrc/bhf heart protection study[J].Lancet,2002,360(9347):1780-1781,author reply1783-1784.
• [12]Schwartz GG,Olsson AG,Ezekowitz MD,et al.Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes:The miracl study:A randomized controlled trial[J].JAMA,2001,285(13):1711-1718.
• [13]Ridker PM,Morrow DA,Rose LM,et al.Relative efficacy of atorvastatin80mg and pravastatin40mg in achieving the dual goals of low-density lipoprotein cholesterol<70mg/dl and c-reactive protein<2mg/l:An analysis of the prove-it timi-22 trial[J].J Am Coll Cardiol,2005,45(10):1644-1648.
• [14]de Lemos JA,Blazing MA,Wiviott SD,et al.Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes:Phase z of the a to z trial[J].JAMA,2004,292(11):1307-1316.
• [15]Holme I,Cater NB,Faergeman O,et al.Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease.Insights from the incremental decrease in end-points through aggressive lipid-lowering trial(ideal)[J].Ann Med,2008,40(6):456-464.
• [16]Austin PC,Mamdani MM.Impact of the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction22/reversal of atherosclerosis with aggressive lipid lowering trials on trends in intensive versus moderate statin therapy in ontario,canada[J].Circulation,2005,112(9):1296-1300.
• [17]Nissen SE,Nicholls SJ,Sipahi I,et al.Effect of very high-intensity statin therapy on regression of coronary atherosclerosis:The asteroid trial[J].JAMA,2006,295(13):1556-1565.
• [18]Crouse JR,3rd,Grobbee DE,O'Leary DH,,et al.Measuring effects on intima media thickness:An evaluation of rosuvastatin in subclinical atherosclerosis--the rationale and methodology of the meteor study[J].Cardiovasc Drugs Ther,2004,18(13):231-238.
• [19]Kapur NK.Rosuvastatin:A highly potent statin for the prevention and management of coronary artery disease[J].Expert Rev Cardiovasc Ther,2007,5(2):161-175.
• [20]Briguori C,Colombo A,Airoldi F,et al.Statin administration before percutaneous coronary intervention:Impact on periprocedural myocardial infarction[J].Eur Heart J,2004,25(20):1822-1828.
• [21]Petretta M,Costanzo P,Perrone-Filardi P,et al.Impact of gender in primary prevention of coronary heart diseasewith statin therapy:A meta-analysis[J].Int J Cardiol,2010,138(1):25-31.
• [22]Di Sciascio G,Patti G,Pasceri V,et al.Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention:Results of the armyda-recapture(atorvastatin for reduction of myocardial damage during angioplasty)randomized trial[J].J Am Coll Cardiol,2009,54(6):558-565.
• [23]Patti G,Pasceri V,Colonna G,et al.Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention:Results of the armyda-acs randomized trial[J].J Am Coll Cardiol,2007,49(12):1272-1278.